[HTML][HTML] Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition

Q Li, J Wu, P Wei, Y Xu, C Zhuo, Y Wang… - American journal of …, 2015 - ncbi.nlm.nih.gov
Q Li, J Wu, P Wei, Y Xu, C Zhuo, Y Wang, D Li, S Cai
American journal of cancer research, 2015ncbi.nlm.nih.gov
Forkhead box protein C2 (FOXC2) plays a vital role in carcinogenesis; however, its
significance and prognostic value in colon cancer remain unclear. In this study, FOXC2
expression was analyzed in a tissue microarray (TMA) containing 185 samples of primary
colon cancer tumor samples and in human colon cancer cell lines. The effect of FOXC2 on
cell proliferation, tumorigenesis, and metastasis was examined in vitro and in vivo. FOXC2
was overexpressed in human colon cancer cells and tissues, and correlated with colon …
Abstract
Forkhead box protein C2 (FOXC2) plays a vital role in carcinogenesis; however, its significance and prognostic value in colon cancer remain unclear. In this study, FOXC2 expression was analyzed in a tissue microarray (TMA) containing 185 samples of primary colon cancer tumor samples and in human colon cancer cell lines. The effect of FOXC2 on cell proliferation, tumorigenesis, and metastasis was examined in vitro and in vivo. FOXC2 was overexpressed in human colon cancer cells and tissues, and correlated with colon cancer progression and patient survival. Functional study demonstrated that FOXC2 promoted cell growth, cell migration, and tumor formation in nude mice, whereas knockdown of FOXC2 by short hairpin RNA (shRNAs) significantly suppressed cell growth, cell migration and tumor formation. Further study found that FOXC2 enhanced AKT activity with subsequent GSK-3β phosphorylation and Snail stabilization, and then induced epithelial-mesenchymal transition (EMT) and promoted tumor invasion and metastasis. Collectively, FOXC2 promotes colon cancer metastasis by facilitating EMT and acts as a potential prognostic factor and therapeutic target in colon cancer.
ncbi.nlm.nih.gov